STAT5 Tetramerization in Autoimmune-mediated Neuroinflammation
Project Number1R01AI167972-01A1
Former Number1R56AI167972-01
Contact PI/Project LeaderWAN, EDWIN CHI KEUNG
Awardee OrganizationWEST VIRGINIA UNIVERSITY
Description
Abstract Text
Project Summary/Abstract
Multiple sclerosis (MS) is an immune-mediated disease that impacts approximately 2.3 million people world-
wide. MS is caused by the activation and the complex interactions between different immune cell types that
cause inflammation in the central nervous system (CNS), which leads to demyelination and axonal degeneration.
A validated animal model of multiple sclerosis, experimental autoimmune encephalomyelitis (EAE), has been
utilized to demonstrate that the cognate interactions between CD4+ T cells and monocyte-derived cells (MDCs),
defined here a mixed population of dendritic cells and macrophages differentiated from monocytes during the
autoimmune-driven neuroinflammation, are required for the pathogenesis of EAE. The overall goal of this
proposal is to identify signaling pathways and their downstream effector mediators that regulate the interactions
of CD4+ T cells and MDCs within CNS that promote the pathogenesis of EAE. Signal transducers and activators
of transcription 5A and 5B (STAT5A and STAT5B) play a critical role in mediating cellular responses following
stimulation of cytokines, interferons, growth factors. The activated STAT5 proteins can form dimers and
tetramers. The biological functions of STAT5 tetramers are not fully understood. Using a Stat5a-Stat5b N-domain
double knock-in (DKI) mouse strain, in which STAT5 tetramers cannot be formed but STAT5 dimers are
unaffected, we found that STAT5 tetramers promote the pathogenesis of EAE. The mild EAE phenotype in DKI
mice correlates with reduced interactions of CD4+ T cells and monocytes/MDCs in the spinal cord meninges
during EAE. We further demonstrated that STAT5 tetramer activation by cytokine GM-CSF promotes monocyte
differentiation into dendritic cells and the expression of chemokine CCL17. Correspondingly, the expression of
CCL17 in the spinal cords is significantly reduced in DKI mice during EAE. Importantly, mice receiving STAT5
tetramer-deficient Th17 cells treated with CCL17 developed more severe EAE with earlier onset of the disease
compared with mice receiving cells without CCL17 treatment. Our central hypothesis is that GM-CSF-mediated
STAT5 tetramerization is critical for facilitating the interactions of pathogenic Th17 cells and monocytes/MDCs
in the spinal cord meninges via a CCL17-dependent mechanism, and these cell interactions are required to
promote the pathogenesis of EAE. We will test our hypothesis in three specific aims. In Aim 1, we will utilize
different EAE induction strategies to determine the pathogenic role of STAT5 tetramers in Th17 cells and
monocytes/MDCs during EAE. In Aim 2, we will test our hypothesis that STAT5 tetramer signaling promotes
monocyte differentiation and Th17 cell-MDC interactions at the spinal cord meninges during EAE using intravital
imaging technique. In Aim 3, we will investigate the mechanism by which CCL17 promotes the pathogenesis of
EAE. Specifically, we will test our hypothesis that CCL17 increases the affinity of integrin VLA-4 on Th17 cells,
thereby facilitates Th17 cell-MDC interactions. Targeting the pathways and mediators that control the interactions
between CD4+ T cells and MDCs within CNS may become a novel strategy for the treatments of MS.
Public Health Relevance Statement
Project Narrative
Multiple sclerosis (MS) is the most common neuroinflammatory disease among young adults. The overall goal
of this proposal is to identify the signaling pathways and their effector mediators that regulate the interactions of
pathogenic CD4+ T cells and antigen-presenting cells within the central nervous system that exacerbate
neuroinflammation. Targeting these pathways and mediators may become a novel strategy for the treatments of
MS.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
191510239
UEI
M7PNRH24BBM8
Project Start Date
17-January-2024
Project End Date
30-November-2028
Budget Start Date
17-January-2024
Budget End Date
30-November-2024
Project Funding Information for 2024
Total Funding
$529,781
Direct Costs
$348,540
Indirect Costs
$181,241
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$529,781
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R01AI167972-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01AI167972-01A1
Patents
No Patents information available for 1R01AI167972-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01AI167972-01A1
Clinical Studies
No Clinical Studies information available for 1R01AI167972-01A1
News and More
Related News Releases
No news release information available for 1R01AI167972-01A1
History
No Historical information available for 1R01AI167972-01A1
Similar Projects
No Similar Projects information available for 1R01AI167972-01A1